Oct 11, 2021 · the fda approval was based on data from the true-ad (topical ruxolitinib evaluation in atopic dermatitis) clinical trial program, consisting of two randomized, double-blind, vehicle-controlled phase iii studies (true-ad1 and true-ad 2) assessing the safety and efficacy of ruxolitinib in more than 1,200 adolescents and adults with mild-to-moderate. "/>